Arcus Biosciences (RCUS) News
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
15.62-0.16 (-1.01%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RCUS news summary
We found 13 recent headlines mentioning Arcus Biosciences (RCUS): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, Seeking Alpha, Investing.com. For price context, RCUS is down 1.01% at $15.62. The most recent story, "Arcus Biosciences, Inc. Reports Third-Quarter 2026 Financial Results", was published by Nasdaq on Nov 4, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Arcus Biosciences headlines
- Arcus Biosciences, Inc. Reports Third-Quarter 2026 Financial ResultsArcus Biosciences, Inc. reported its financial results for the third quarter ended September 30, 2026. Revenues were $9 million for the third-quarter 2026, compared to $26 million for the same period…Nasdaq
- Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline UpdateHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…Business Wire
- Arcus Biosciences prices $250M public offering at $17.50 per shareSeeking Alpha
- Why is Arcus Biosciences stock sliding today?Investing.com
- Arcus Biosciences, Inc. Estimates $694.0 million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2026Arcus Biosciences, Inc. announced preliminary estimates indicating that the company had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. This…Nasdaq
- Arcus Biosciences slides 20% on stock offering, kidney-cancer dataSeeking Alpha
- Arcus Biosciences stock falls on public offering announcementInvesting.com
- Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmNEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS) breached…PR Newswire
- Arcus Biosciences announces public stock offeringSeeking Alpha
- Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.NasdaqSMMT, AZN, GSK, RCUS
- Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseBiogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqBIIB, RCUS
- Why is Arcus Biosciences stock sliding today?Investing.com
- JP Morgan Initiates Coverage of Arcus Biosciences at OverweightFintel reports that on October 14, 2026, JP Morgan initiated coverage of Arcus Biosciences (NYSE:RCUS) with a Overweight recommendation.Prior to this rating action, the stock closed at $22.51 on…Nasdaq